XLOS-Observed P151L MID1 Mutation Resulted in a Gain of E3 Ligase Activity Due to a Difference in Interaction with the Ube2D1 E2 Enzyme
- 1Department of Chemistry, George Washington University, Washington, DC 20052, USA
- 2Division of Pharmaceutical Chemistry, University of Vienna, Josef-Holaubek-Platz 2, 2F 353, A-1090 Vienna, Austria
- 3School of Pharmacy, Health Sciences, University of Eastern Finland, Yliopistonranta 3, 70210 Kuopio, Finland
Abstract
The human midline-1 (MID1) protein is an important E3 ubiquitin ligase that regulates cellular homeostasis by catalyzing the ubiquitination of protein phosphatase 2A (PP2A), alpha4 (α4), and Fu kinase. The E3 ubiquitin ligase activity of MID1 is mediated by its N-terminal zinc-binding RING and B-box1 domains. In contrast to the RING domain, which promotes poly-ubiquitination, the B-box1 domain predominantly catalyzes auto-mono-ubiquitination. Our current study provides insights into the molecular basis of enhanced mono- and poly-auto-ubiquitination associated with the X-linked Opitz syndrome (XLOS)-observed P151L mutation in the MID1 B-box1 domain compared with the wild-type (WT) protein. Structural studies revealed that this gain of activity is likely due to a different binding mechanism with the Ube2D1 E2 enzyme compared with the WT B-box1. NMR spectroscopy and predictive modeling revealed that while the overall global fold remains intact, the P151L mutation results in its central α-helix extending at its C-terminus and alters the dynamic properties of residues of loop 2, a critical region for interacting with the E2 enzyme. Molecular dynamics (MD) simulations confirm the structural stability of P151L mutant and additionally revealed altered backbone conformations, indicating structural reorganization around the E2-interaction surface. These changes may provide an explanation for the altered Ube2D1 binding mode and impact the P151L mutant binding the Ube2D1 E2 enzyme on the opposite side to where the WT B-box1 binds and adjacent to the canonical RING:E2 interface. The binding interaction may also provide a rationale for why P151L MID1 is unable to polyubiquitinate α4.
Related
- The SETD2 L1609P mutation found in leukemia disrupts methyltransferase activity and reduces histone H3K36 trimethylation
- Differential histone tail citrullination by protein arginine deiminases observed via NMR spectroscopy
- Evaluating and choosing experimental parameters for shifted excitation Raman difference spectroscopy: a quantitative study
- SF3b inhibitors suppress proliferation of nonsmall cell lung cancer cells irrespective of EGFR mutation status
- CRISPR/Cas9‐Mediated Correction of the SLC25A38 Mutation in a Patient With Sideroblastic Anemia
BibTeX
@article{kaur2026xlosobserved,
title = {{XLOS-Observed P151L MID1 Mutation Resulted in a Gain of E3 Ligase Activity Due to a Difference in Interaction with the Ube2D1 E2 Enzyme}},
author = {Anupreet Kaur and Katharine M. Wright and Juho Karuaho and Maija Lahtela-Kakkonen and Michael A. Massiah},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272210213},
url = {https://www.mdpi.com/1422-0067/27/22/10213},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - XLOS-Observed P151L MID1 Mutation Resulted in a Gain of E3 Ligase Activity Due to a Difference in Interaction with the Ube2D1 E2 Enzyme
AU - Anupreet Kaur
AU - Katharine M. Wright
AU - Juho Karuaho
AU - Maija Lahtela-Kakkonen
AU - Michael A. Massiah
PY - 2026
DA - 2026/11/14
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272210213
UR - https://www.mdpi.com/1422-0067/27/22/10213
AB - The human midline-1 (MID1) protein is an important E3 ubiquitin ligase that regulates cellular homeostasis by catalyzing the ubiquitination of protein phosphatase 2A (PP2A), alpha4 (α4), and Fu kinase. The E3 ubiquitin ligase activity of MID1 is mediated by its N-terminal zinc-binding RING and B-box1 domains. In contrast to the RING domain, which promotes poly-ubiquitination, the B-box1 domain predominantly catalyzes auto-mono-ubiquitination. Our current study provides insights into the molecular basis of enhanced mono- and poly-auto-ubiquitination associated with the X-linked Opitz syndrome (XLOS)-observed P151L mutation in the MID1 B-box1 domain compared with the wild-type (WT) protein. Structural studies revealed that this gain of activity is likely due to a different binding mechanism with the Ube2D1 E2 enzyme compared with the WT B-box1. NMR spectroscopy and predictive modeling revealed that while the overall global fold remains intact, the P151L mutation results in its central α-helix extending at its C-terminus and alters the dynamic properties of residues of loop 2, a critical region for interacting with the E2 enzyme. Molecular dynamics (MD) simulations confirm the structural stability of P151L mutant and additionally revealed altered backbone conformations, indicating structural reorganization around the E2-interaction surface. These changes may provide an explanation for the altered Ube2D1 binding mode and impact the P151L mutant binding the Ube2D1 E2 enzyme on the opposite side to where the WT B-box1 binds and adjacent to the canonical RING:E2 interface. The binding interaction may also provide a rationale for why P151L MID1 is unable to polyubiquitinate α4.
SN - 1422-0067
ER -